Business
Bio-Techne Corporation and Leica Biosystems are Accelerating Disease Research with RNAscope™ COVID-19 Probes and the BOND RX*
Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform MINNEAPOLIS, Aug. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation
About this update from Bio-techne Corp
[{"type":"text","content":"Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform\n\n\nMINNEAPOLIS, Aug. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*, Leica's staining platform, for research use only. Researchers now have the ability to automate their COVID-19 research protocols, reducing manual labor and turnaround time. \n\"The Bio-Techne R&D team quickly developed COVID-19 specific probes when the genetic sequence of this virus was released,\" commented Kim Kelderman, President, Diagnostics and Genomics Segment, Bio-Techne Corporation. \"We believe RNAscope™ probes will enable researchers to gain a greater understanding of the pathogenesis of this disease. The availability of these probes on the automated Leica Biosystems platform will expediate important discoveries,\" Kim added.\nThe BOND RX* is a flexible, open platform with the capability to run Bio-Techne RNAscope™ (duplex and multiplex) protocols, allowing for boundless innovation. \n\"We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,\" said Melissa Aquino, President, Leica Biosystems. \"The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment to support researchers in addressing the pandemic.\"\nThe RNAscope™ probes are designed to detect SARS-Cov-2 viral RNA, SARS-Cov-2 viral replication sequences, and cellular receptors targeted by the virus, including ACE2 and TMPRSS2. \n*For Research Use Only, Not for Use in Clinical Diagnostic Procedure\nAbout Bio-Techne\nBio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These ...